PCDHGA9

Across TCGA pan-cancer cohorts, PCDHGA9 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PCDHGA9 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher PCDHGA9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCDHGA9 expression acts as an unfavorable survival marker.

PRAD, UCEC, and BLCA are the cancer types where PCDHGA9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.153	0.888	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	DFS	Median	All	0.211	0.522	.025	6	view →
HNSC	OS	Median	IV	0.162	0.639	.030	6	view →
LUAD	OS	Median	IV	0.153	0.714	.012	6	view →
LUSC	OS	Median	II,III,IV	0.318	0.622	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PCDHGA9–PRAD (DFS)

Open the PRAD breakdown →